Abstract: The present invention relates to a hypoxia-inducible factor (HIF) activator, or a pharmaceutically acceptable salt or solvate thereof, for use in promoting tissue repair. The HIF activator, or the pharmaceutically acceptable salt or solvate thereof, is for use with a prototypical tissue-protective cytokine, or a pharmaceutically acceptable salt or solvate thereof, which is administered exogenously to the body being treated.

Abstract: The techniques described herein may provide techniques for precise and fully-automatic on-site software failure diagnosis that overcomes issues of existing systems and general challenges of in-production software failure diagnosis. Embodiments of the present systems and methods may provide a tool capable of automatically pinpointing a fault propagation chain of program failures, with explicit symptoms. The combination of binary analysis, in-situ/identical replay, and debugging registers may be used together to simulate the debugging procedures of a programmer automatically. Overhead, privacy, transparency, convenience, and completeness challenges of in-production failure analysis are improved, making it suitable for deployment uses.

Abstract: A bioelectric interface is provided. The bioelectric interface comprises a case having a channel configured to hold a nerve. An electrode array is slidably coupled to the case, wherein the electrode array comprises a number of electrode shanks. The case restricts movement of the electrode array to one degree of freedom toward or away from the nerve held in the channel for insertion of the electrode shanks into the nerve.

Abstract: Provided herein are methods to identify TCR-recognizing cancer-specific antigens, and TCR-engineered T cells having antigen-specific cytotoxic activity. Provided herein are engineered T lymphocytes produced by the methods described herein. Provided herein are methods of treating cancer in a subject comprising administering the engineered T lymphocytes described herein. Provided herein are antibodies, or fragments thereof, produced by the methods described herein. Provided herein are methods of treating cancer in a subject comprising administering the antibodies described herein to a subject. In some embodiments, the therapeutic compositions (e.g., engineered lymphocytes, antibodies, etc.) and methods herein are provided as part of a kit or system.

Abstract: In various embodiments, the present invention is directed to a melanin composition extracted from black knot fungus (Apiosporina morbosa) using an acid-base extraction technique. In one or more embodiments, the melanin composition is extracted from the black outer layer of a black knot fungus by obtaining a powder including a black outer part of one or more black knot fungus, adding a quantity of an aqueous solution comprising one or more base, heating the mixture to solubilize a melanin in the aqueous solution to form a black alkaline supernatant containing said melanin, adding one or more acids to said black alkaline supernatant until the melanin precipitates out of said black alkaline supernatant, said melanin precipitate further comprising proteins, carbohydrates, and lipids; collecting the melanin precipitate and adding one or more acids to hydrolyze some or all of said proteins, carbohydrates, and lipids and produce the melanin composition.

Abstract: A method for fabricating a three-dimensional (3D) stacked integrated circuit. Pick-and-place strategies are used to stack the source wafers with device layers fabricated using standard two-dimensional (2D) semiconductor fabrication technologies. The source wafers may be stacked in either a sequential or parallel fashion. The stacking may be in a face-to-face, face-to-back, back-to-face or back-to-back fashion. The source wafers that are stacked in a face-to-back, back-to-face or back-to-back fashion may be connected using Through Silicon Vias (TSVs). Alternatively, source wafers that are stacked in a face-to-face fashion may be connected using Inter Layer Vias (ILVs).

Abstract: A method of carrying out mass spectrometry, comprising: using an electrostatic or electrodynamic ion trap to contain a plurality of ions, each ion having a mass to charge ratio, the ions having a first plurality of mass to charge ratios, each ion following a path within the electrostatic or electrodynamic ion trap having a radius; and for each of a second plurality of the mass to charge ratios: modulating the radii of the ions in a mass to charge ratio-dependent fashion dependent upon the mass to charge ratio; fragmenting the ions thus modulated in a radius-dependent fashion; and determining a mass spectrum of the ions.

Abstract: Crosslinked membranes for anion exchange applications, and methods of making and using the same, are described.

Abstract: A method of providing an article having a set of directional channels, including a first directional channel, therein is described. The method comprises preparing a mixture including particles comprising a first material and a first binding agent. The method comprises providing an article precursor by surrounding a pattern comprising a second material with the mixture. The method comprises heating the article precursor thereby coalescing the particles to provide the article. The method comprises removing the pattern by reacting the second material to form a gaseous product, thereby providing the set of directional channels in the article, wherein the set of directional channels corresponds with the removed pattern. Such an article is also described.

Abstract: A method of analysing an aqueous fluid comprising obtaining a 2D-IR spectrum of a sample of the aqueous fluid using a 2D-IR spectrometer configured to apply a sequence of IR pulses to the sample, wherein the sequence comprises a pump process followed by a probe pulse, where the pump process is a single pump pulse or a sequence of a first pump pulse and a second pump pulse, and a waiting time Tw between applying the single pump pulse or the second pump pulse and applying the probe pulse is from 150 to 350 fs.

Abstract: A female urethral catheter guide includes a guide body defining a first body portion having a first end and a second body portion having a second end. The first body portion includes a longitudinally extending catheter support groove formed in a surface thereof, and the second body portion includes a radially outwardly extending tunnel portion having a catheter tunnel formed therein, wherein the catheter tunnel is connected to the catheter support groove and the second end of the second body portion is rounded and defines a vaginal support end.

Abstract: Aspects of the subject disclosure may include, for example, embodiments that comprise obtaining a data budget associated with a communication session for streaming video content over a communication network from a video content server, determining a first portion of the data budget that is associated with a first segment of the video content, and obtaining quality information associated with the video content from the video content server over the communication network. Further embodiments can include identifying a first group of tracks for the first segment, and determining a first target quality for the first segment based on the first portion of the data budget and the quality information. Other embodiments are disclosed.

Abstract: Aspects of the subject disclosure may include, for example, obtaining data budget for a communication session, identifying video content associated with the communication session, and determining a group of segments associated with the video content. Further embodiments can include determining a segment size for each of the group of segments, identifying a base track for each segment of the group of segments based on the segment size for each segment of the group of segments and the data budget, and identifying a target track for each segment of the group of segments based on the base track for each segment of the group of segments, the segment size for each segment of the group of segments, and the data budget. Additional embodiments can include providing a request for the target track for each segment to a video content server over a communication network. Other embodiments are disclosed.

Abstract: The present invention relates to methods of diagnosis and therapy for neurodegenerative diseases and disorders.

Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.

Abstract: Provided herein are methods of selecting cancer patients for treatment with poziotinib as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with poziotinib alone or in combination with HER2/HER3 targeting antibodies.

Abstract: The present disclosure relates to methods and products for reducing adhesions. In certain embodiments, the present disclosure provides a method of reducing adhesions in a subject, the method comprising exposing a region in the subject susceptible to formation of an adhesion to an agent having iron chelation and/or antioxidant activity, thereby reducing adhesions in the subject.

Abstract: A method of three-dimensional stereolithography printing a thiourethane polymer part using the vat resin. Adding a resin to a vat of a three-dimensional stereolithography printer, the resin a liquid mixture including: a first type of monomer including two or more thiol functional groups, a second type of monomer including two or more isocyanate functional groups, a photolatent base, an anionic step-growth polymerization reaction inhibitor and a light absorber. The photolatent base is decomposable upon exposure to a light to form a non-nucleophillic base catalyst having a pKa greater than 7. The anionic step-growth polymerization reaction inhibitor has an acidic group configured to form an acid-base pair with the non-nucleophillic base. The light absorber has an absorbance in the liquid mixture that is greater than an absorbance of the photolatent base at a wavelength of the light used for the exposure.

Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.

Abstract: It is an object of the present invention to provide a fluorescence imaging probe capable of selectively visualizing target cells such as cells expressing ?-galactosidase (lacZ expressing cells) at a single-cell level in a red fluorescence region, and of performing co-staining together with GFP.